Risk Management Guidelines
The National Comprehensive Cancer Network (NCCN) is a group of experts in management of hereditary cancer. The NCCN provides guidelines for risk management for people with hereditary risk for cancer. These guidelines are update regularly based on the latest research and medical knowledge.
These guidelines are available for several genes which have been shown to increase a person’s risk of cancer. For some genes, guidelines are not currently available because more research is needed before there is enough evidence to make recommendations on how to manage cancer risk in people with mutations in these genes.
We have created a simple document to present the guidelines for each of the genes associated with an increased risk of breast cancer. We invite you to share this document with your healthcare provider and at-risk family members.
You can download or print the PDF format for the gene and gender you are interested in by clicking on the link on this webpage.
We will update this resource each time the NCCN will update their guidelines and will add guidelines for new breast cancer associated genes as they become available. Therefore, we suggest that you check this information on our website annually to ensure that you have access to the latest recommendations.
These documents are for informational purposes and do not constitute a personalised recommendation. It remains important for people with pathogenic / likely pathogenic variant (mutation) in these genes to consult with their healthcare provider(s), including medical specialists (ex. surgeons, genetic experts, etc.) to determine the best risk management plan based on their personal and family medical history and other circumstances, including access to some options that may vary from one medical center to another.
|NCCN Guidelines for WOMEN||NCCN Guidelines for MEN|
|PTEN (PTEN Hamartoma Tumor Syndrome)||PTEN (PTEN Hamartoma Tumor Syndrome)|
|STK11 (Peutz-Jeghers Syndrome)||STK11 (Peutz-Jeghers Syndrome)|
|TP53 (Li-Fraumeni Syndrome)||TP53 (Li-Fraumeni Syndrome)|